Professor of Pathology, University Tex Houston
Pathology
Dr. Aysegul A. Sahin, MD
|
|
Give Review
Aysegul Sahin practices Pathology. He over the years received 3 awards: "America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Aysegul Sahin is a published doctor. He has 102 papers published. The most current publication "Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Work..." He is registered with Medicare and accepts Medicare payments.
Publications
- Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth.
- Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients With Stage II Breast Cancer.
- Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis.
- 14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2.
- Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer.
- Breast pathology second review identifies clinically significant discrepancies in over 10% of patients.
- Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer.
- Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
- Definition of PKC-α, CDK6 and MET as therapeutic targets in triple-negative breast cancer.
- Loss of LRIG1 Locus Increases Risk of Early and Late Relapse of Stage I/II Breast Cancer.
- Increased gene copy number of VAMP7 disrupts human male urogenital development through altered estrogen action.
- Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer.
- Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment.
- Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
- Open label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC vs. the combination of paclitaxel and everolimus followed by ...
- Too Much, Too Little, or Just Right? Tumor Margins in Women Undergoing Breast-Conserving Surgery.
- Concordance of Genomic Alterations Between Primary and Recurrent Breast Cancer.
- Y-chromosome microdeletions are not associated with SHOX haploinsufficiency.
- Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.
- Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies.
- SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
- DEAR1 Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-β-Driven Epithelial-Mesenchymal Transition.
- Impact of Identification of Internal Mammary Sentinel Lymph Node Metastasis in Breast Cancer Patients.
- Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer.
- Genetic variants in the vitamin D pathway and breast cancer disease-free survival.
- Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy.
- Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer.
- American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns.
- Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current...
- Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
- Occult axillary lymph node metastasis do not have prognostic significance in early stage breast cancer.
- Copy Number Imbalances Between Screen and Symptom-Detected Breast Cancers and Impact on Disease-free Survival.
- Age and Associated Fibrocystic Changes are Prognostically Significant in Patients with Small Node-Negative (T1a,bN0) Invasive Breast Cancer.
- Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Bas...
- Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer.
- PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer.
- Delays in Primary Surgical Treatment Are Not Associated with Significant Tumor Size Progression in Breast Cancer Patients.
- Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy.
- Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.
- Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing T...
- PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
- Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells.
- Identification of a novel estrogen receptor-alpha variant and its upstream splicing regulator.
- Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexa...
- Is it too soon to start reporting HER2 genetic heterogeneity?
- AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
- Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.
- Identification and biologic significance of micrometastases in axillary lymph nodes in patients with invasive breast cancer.
- DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
- Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node me...
- Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer pa...
- Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.
- Staging of breast cancer in the neoadjuvant setting.
- IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas.
- Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
- Relationship between epidemiologic risk factors and breast cancer recurrence.
- IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.
- Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy.
- Role for intraoperative margin assessment in patients undergoing breast-conserving surgery.
- Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis.
- Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth fact...
- Comparison of full-field digital mammography and screen-film mammography for detection and characterization of simulated small masses.
- Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation strati...
- LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system.
- Benign breast diseases: classification, diagnosis, and management.
- Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
- The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
- Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.
- Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
- Functional implications of altered subcellular localization of PELP1 in breast cancer cells.
- Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
- CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation.
- The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstituti...
- Improving local control with breast-conserving therapy: a 27-year single-institution experience.
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized tr...
- Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
- Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets.
- p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B.
- Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
- Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry.
- Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma.
- Breast conservation after neoadjuvant chemotherapy.
- Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy a...
- Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
- Contralateral prophylactic mastectomy. Predictors of significant histologic findings.
- Telomerase in breast cancer: a critical evaluation.
- Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radio...
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
- Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields.
- Expression of c-kit proto-oncogene product in breast tissue.
- Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
- Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes.
- Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: histologic predictors of malignancy.
- Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
- Invasive ductal carcinoma of the breast with a microglandular adenosis pattern.
- p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells.
- STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis.
- Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast.
- Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
- Nuclear factor-kappa B as a predictor of treatment response in breast cancer.
- Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Work...
Schools
Ankara University Medical Faculty
Oregon Health and Science University
University Ia
Doctors Specialties
- Pathology
Accepted Insurances
- Aetna HMO
- CHAMPVA
- Cigna
- Commercial Insurance Company
- Coventry Health Care
- GEHA
- Humana
- Medical Mutual of Ohio
- Medicare MCR
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
University of Texas MD Anderson Cancer Center -
University of Iowa Hospitals and Clinics -
Oregon Health & Science University -
Ankara University Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356438196 |
| Last Name Of The Provider | SAHIN |
| First Name Of The Provider | AYSEGUL |
| View All |
Similar Doctors
|
|
Dr. Constance T. Albarracin, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Farinaz Arbab, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gene Landon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristina L. Burt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ragini D. Lakhia, MD |
|
|
Dr. Carolina C. Gutierrez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shimin Hu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lori A. Peters, MD
This Doctor is OpenDoctor Recommended.
|